Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Meningococcal B Disease”

102 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 102 results

Large-scale testing (Phase 3)Study completedNCT00384397
What this trial is testing

2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Who this might be right for
Meningococcal MeningitisMeaslesMumps+2 more
Sanofi Pasteur, a Sanofi Company 1,128
Testing effectiveness (Phase 2)Study completedNCT00134719
What this trial is testing

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Who this might be right for
Neisseria MeningitidisHaemophilus Influenzae Type b
GlaxoSmithKline 1,104
Large-scale testing (Phase 3)Study completedNCT01339923
What this trial is testing

A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 1,409
Large-scale testing (Phase 3)Study completedNCT01423084
What this trial is testing

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis 344
Large-scale testing (Phase 3)Active Not RecruitingNCT06446752
What this trial is testing

BIYELA - Bexsero Immunisation in Young Women in Africa

Who this might be right for
GonorrheaGonorrhea of PharynxGonorrhea of Anus+1 more
University of Washington 1,100
Large-scale testing (Phase 3)Study completedNCT01894919
What this trial is testing

Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28

Who this might be right for
Meningoccocal DiseaseMeningococcal Meningitis
Novartis Vaccines 851
Testing effectiveness (Phase 2)Study completedNCT02946385
What this trial is testing

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 604
Large-scale testing (Phase 3)Study completedNCT01553279
What this trial is testing

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Who this might be right for
Neisseria MeningitidisBacterial InfectionsVirus Diseases
MCM Vaccines B.V. 284
Early research (Phase 1)Study completedNCT00879814
What this trial is testing

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Who this might be right for
Meningitis, Meningococcal
Pfizer 48
Large-scale testing (Phase 3)Study completedNCT01139021
What this trial is testing

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Who this might be right for
Meningococcal Disease
Novartis Vaccines 508
Post-approval studies (Phase 4)Looking for participantsNCT06832514
What this trial is testing

Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

Who this might be right for
Meningococcal Meningitis, Serogroup BTransgender PersonsSex Differences in Immune Response+1 more
University Ghent 250
Not applicableStudy completedNCT01544764
What this trial is testing

Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina

Who this might be right for
Adolescent Health ServicesImmunization
University of North Carolina, Chapel Hill 91
Testing effectiveness (Phase 2)Ended earlyNCT00798304
What this trial is testing

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

Who this might be right for
Meningitis, Meningococcal
Pfizer 46
Post-approval studies (Phase 4)UnknownNCT06209398
What this trial is testing

Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine

Who this might be right for
Hand, Foot and Mouth Disease
Jiangsu Province Centers for Disease Control and Prevention 510
Testing effectiveness (Phase 2)UnknownNCT02919293
What this trial is testing

Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Who this might be right for
MeningitisMeningococcal MeningitisMeningococcal Infections
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd 360
Large-scale testing (Phase 3)Study completedNCT00326118
What this trial is testing

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Who this might be right for
Haemophilus Influenzae Type bNeisseria Meningitidis
GlaxoSmithKline 433
Large-scale testing (Phase 3)Study completedNCT02305446
What this trial is testing

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

Who this might be right for
Meningitis, Meningococcal, Serogroup B
Novartis 55
Testing effectiveness (Phase 2)Study completedNCT05294588
What this trial is testing

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Who this might be right for
Gonorrhea Male
University of North Carolina, Chapel Hill 65
Large-scale testing (Phase 3)Study completedNCT00847145
What this trial is testing

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Who this might be right for
Meningococcal Disease
Novartis Vaccines 2,249
Testing effectiveness (Phase 2)Study completedNCT00962624
What this trial is testing

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults

Who this might be right for
Meningococcal Meningitis, Serogroup AMeningococcal Meningitis, Serogroup BMeningococcal Meningitis, Serogroup C+2 more
Prof. Elizabeth Miller 38
Load More Results